Atlas Venture
http://www.atlasventure.com/Atlas Venture is a venture capital firm that invests in early stage technology and life sciences businesses. Since the firm’s founding in 1980, the firm has helped build over three hundred companies. Since 1995, forty seven of its investments have been acquired and more than forty have gone public, with an aggregate market capitalization of over $20 billion.
View Older Stories View More Recent Stories
-
Form 13F-HR Atlas Venture Advisors, For: Sep 30
-
Form 3 Korro Bio, Inc. For: Nov 03 Filed by: Atlas Venture Associates XI, L.P.
-
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
-
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
-
Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX
-
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics
-
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
-
Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning
-
Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody
-
Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa
-
Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer
-
Form SC 13D/A Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Form 4 Disc Medicine, Inc. For: Sep 14 Filed by: Atlas Venture Associates X, LLC
-
Verve Therapeutics (VERV) Appoints Frederick T. Fiedorek as Chief Medical Officer
-
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Form SC 13D/A Dianthus Therapeutics, Filed by: Atlas Venture Fund X, L.P.
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Mariana Oncology Announces $175 Million Series B Financing
-
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
-
Form 4 Disc Medicine, Inc. For: Aug 14 Filed by: Atlas Venture Associates Opportunity I, L.P.
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Form 13F-HR Atlas Venture Life Scien For: Jun 30
-
Form 13F-NT Atlas Venture Associates For: Jun 30
-
Form 13F-NT Atlas Venture Associates For: Jun 30
-
Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
-
Form 13F-HR Atlas Venture Associates For: Jun 30
-
Form 13F-HR Atlas Venture Advisors, For: Jun 30
-
Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer
-
Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia and other Neurodegenerative Disorders at the Alzheimer's A
-
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
-
Frequency Therapeutics (FREQ) to Merge with Korro Bio
-
Korro Bio and Frequency Therapeutics Announce Merger Agreement
-
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
-
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
-
Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
-
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Trans
-
Form SC 13D/A Viridian Therapeutics, Filed by: Atlas Venture Fund VII L P
-
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
-
Intellia Therapeutics (NTLA) Announces Resignation of Jean-François Formela from Board
-
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
-
Be Biopharma to Present at the Jefferies Healthcare Conference
-
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems
-
Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting
-
Form 13F-HR Atlas Venture Life Scien For: Mar 31
-
Kinaset Therapeutics to Present at the American Thoracic Society (ATS) 2023 Respiratory Innovation Summit
-
Form 13F-NT Atlas Venture Associates For: Mar 31
-
Form 13F-NT Atlas Venture Associates For: Mar 31

